Salt Lake City, Utah, United States
Driven self-starter and former strategy consultant with extensive experience in competitive intelligence, market research, corporate strategy, and business development. Proven track record of excelling in matrix organizations, managing cross-functional stakeholders, and effectively communicating with senior leadership and direct reports. Skilled in utilizing scientific expertise to inform strategic business decisions across diverse therapeutic areas.
Lead competitive intelligence activities across Cullinan's autoimmune and oncology product pipeline.
• Responsible for day-to-day operations of the CNS-focused business development organization including leading project and process management for entire BD pipeline, managing a team to execute scientific, clinical, and commercial due diligence workstreams, and supporting BOD-facing reporting and governance • Support commercial workstreams at GRIN Therapeutics, a Neurvati SubCo focused on rare pediatric epilepsy and neurodevelopmental disorders
• Built and led competitive intelligence function to track key developments, distill implications, and communicate insights to audience of cross-functional stakeholders: • Led primary and secondary market research in support of corporate objectives such as indication prioritization and KOL engagement strategy • Member of Talaris Therapeutics strategy and transaction team with BOD and investment bank to evaluate and prioritize dozens of exit opportunities culminating in reverse merger with Tourmaline Bio
Selected biopharma strategy consulting experience (non-exhaustive): • Supported enterprise portfolio optimization for a top 10 global pharma by working closely with Portfolio Strategy team to maximize ROI of >$5B R&D budget • Developed a competitive benchmarking assessment of the oncology market by mechanism of action, tumor type, and modality to inform large pharma client’s therapeutic area strategy • Conducted a market research and revenue opportunity assessment to size total addressable market, understand market segmentation, unmet need, and pricing sensitivity, and develop a forecast for a novel pain product • Supported business development strategy for client specialized in GI/hepatology by triaging hundreds of assets based on scientific, clinical, regulatory, and commercial criteria to arrive at most compelling subset of potential licensing/acquisition opportunities • Compiled universe of >1000 oncology, immunology, and neuroscience therapeutic targets across and triaged based on scientific, clinical, and commercial criteria to identify most compelling opportunities to deploy client’s AI-driven R&D platform • Conducted a market research assessment to understand landscape of immunological analytical technologies and identify strategic growth opportunities
• Supported deal flow by sourcing new deals, performing due diligence, and facilitating financings • Collaborated across venture fund and incubator to build scalable infrastructure that supports growth and development of portfolio companies from seed/Series A onward